Skip to main content
PMC home page
Journal of Urban Health : Bulletin of the New York Academy of Medicine logoLink to Journal of Urban Health : Bulletin of the New York Academy of Medicine
. 2004 Mar;81(1):38–47. doi: 10.1093/jurban/jth086

The content and comprehensiveness of hepatitis C education in methadone maintenance and drug-free treatment units

Shiela M Strauss 1,✉, Janetta M Astone 1, Holly Hagan 1, Don C Des Jarlais 2
PMCID: PMC3456136  PMID: 15047782

Abstract

Although drug users are at elevated risk for hepatitis C virus (HCV) infection, many are uniformed or misinformed about the virus. Drug treatment programs are uniquely situated to provide comprehensive risk-modifying educational programs for decreasing HCV transmission, a strategy advocated in the most recent National Institutes of Health Consensus Development Conference Statement on the Management of Hepatitis C. Given the large proportion of patients that inject drugs in methadone maintenance treatment programs and the high prevalence of HCV among drug injectors, we compared a nationwide sample (N=246) of methadone maintenance treatment programs and drug-free programs regarding the content and comprehensiveness of HCV education. All of these programs provide HCV education to at least some of their patients. Results indicated that, compared to drug-free programs, methadone maintenance treatment programs cover a significantly greater number of HCV-related topics, and that a significantly greater proportion of the methadone programs cover specific topics (e.g., how to avoid transmitting HCV, the importance of testing for HCV, treatment options if HCV positive). Of special concern is that fewer than three quarters of the drug-free programs address what to do if co-infected with human immunodeficiency virus (HIV) and HCV and how to maintain health if HCV positive, and only about half of the drug-free and methadone maintenance treatment programs educate HCV-positive patients about the importance of obtaining vaccinations for hepatitis A and B. Drug treatment programs need to educate patients about the proactive steps these individuals can take to deal with HCV, provide critically needed HCV services, and encourage patients to make full use of these services.

Keywords: Drug treatment programs, Education, Hepatitis C

Full Text

The Full Text of this article is available as a PDF (89.0 KB).

References

  • 1.Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556–562. doi: 10.1056/NEJM199908193410802. [DOI] [PubMed] [Google Scholar]
  • 2.Seeff LB. Natural history of hepatitis C. Am J Med. 1999;107(6B):10S–15S. doi: 10.1016/S0002-9343(99)00374-5. [DOI] [PubMed] [Google Scholar]
  • 3.Centers for Disease Control and Prevention Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease MMWR Morb Mortal Wkly Rep 1998471–39.9450721 [Google Scholar]
  • 4.Heintges T, Wands JR. Hepatitis C virus: epidemiology and transmission. Hepatology. 1997;26:521–526. doi: 10.1002/hep.510260338. [DOI] [PubMed] [Google Scholar]
  • 5.Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology. 1991;12:671–675. doi: 10.1002/hep.1840120409. [DOI] [PubMed] [Google Scholar]
  • 6.Simonetti RG, Camma C, Fiorello F. Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis: a case-control study. Ann Intern Med. 1992;116:97–102. doi: 10.7326/0003-4819-116-2-97. [DOI] [PubMed] [Google Scholar]
  • 7.Yu MC, Tong MJ, Corsaget P. Prevalence of hepatitis B and C viral markers in black and white patients with hepatocellular carcinoma in the United States. J Natl Cancer Inst. 1990;82:1038–1041. doi: 10.1093/jnci/82.12.1038. [DOI] [PubMed] [Google Scholar]
  • 8.Hagan H, Thiede H, Weiss HS, Hopkins SG, Duchin JS, Alexander ER. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health. 2001;91:42–46. doi: 10.2105/ajph.91.1.42. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Thomas DL, Vlahov D, Solomon L, et al. Correlates of hepatitis C virus infections among injection drug users. Medicine. 1995;74:212–220. doi: 10.1097/00005792-199507000-00005. [DOI] [PubMed] [Google Scholar]
  • 10.Best D, Noble A, Finch E, Gossop M, Sidwell C, Strang J. Accuracy of perceptions of hepatitis B and C status: cross sectional investigation of opiate addicts in treatment. Br Med J. 1999;319:290–291. doi: 10.1136/bmj.319.7205.290. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Dhopesh VP, Taylor KR, Burke WM. Survey of hepatitis B and C in an addiction treatment unit. Am J Drug Alcohol Abuse. 2000;26:703–707. doi: 10.1081/ADA-100101903. [DOI] [PubMed] [Google Scholar]
  • 12.Kwiatkowski CF, Fortuin Corsi K, Booth RE. The association between knowledge of hepatitis C virus status and risk behaviors in injection drug users. Addiction. 2002;97:1289–1294. doi: 10.1046/j.1360-0443.2002.00208.x. [DOI] [PubMed] [Google Scholar]
  • 13.Stein MD, Maksad J, Clarke J. Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment. Drug Alcohol Depend. 2001;61:211–215. doi: 10.1016/S0376-8716(00)00144-7. [DOI] [PubMed] [Google Scholar]
  • 14.Rosenblum A, Nuttbrock L, McQuistion HL, Magura S, Joseph H. Hepatitis C and substance use in a sample of homeless people in New York City. J Addict Dis. 2001;20:15–25. doi: 10.1300/J069v20n04_03. [DOI] [PubMed] [Google Scholar]
  • 15.Tortu S, Neaigus A, McMahon J, Hagan D. Hepatitis C among non-injecting drug users: a report. Subst Use Misuse. 2001;36:523–534. doi: 10.1081/JA-100102640. [DOI] [PubMed] [Google Scholar]
  • 16.Bae JP. Assessing the need, use, and developments in mental health/substance abuse care. Health Care Financ Rev. 1997;18:1–4. [PMC free article] [PubMed] [Google Scholar]
  • 17.Chitwood DD, McBride DC, French MT, Comerford M. Health care need and utilization: a preliminary comparison of injection drug users, other illicit drug users, and nonusers. Subst Use Misuse. 1999;34:727–746. doi: 10.3109/10826089909037240. [DOI] [PubMed] [Google Scholar]
  • 18.Contoreggi C, Rexroad VE, Lange WR. Current management of infectious complications in the injecting drug user. J Subst Abuse Treat. 1998;15:95–106. doi: 10.1016/S0740-5472(97)00048-2. [DOI] [PubMed] [Google Scholar]
  • 19.Clapp JD. Organizational factors related to AIDS/HIV education in outpatient substance abuse treatment units. J Health Soc Policy. 1998;9:1–13. doi: 10.1300/J045v09n03_01. [DOI] [PubMed] [Google Scholar]
  • 20.Metzger DS, Navaline H, Woody GE. Drug abuse treatment as AIDS prevention. Public Health Rep. 1998;113(suppl 1):97–106. [PMC free article] [PubMed] [Google Scholar]
  • 21.D’Aunno T, Vaughn TE, McElroy P. An institutional analysis of HIV prevention efforts by the nation’s outpatient drug abuse treatment units. J Health Soc Behav. 1999;40:175–192. doi: 10.2307/2676372. [DOI] [PubMed] [Google Scholar]
  • 22.Friedmann PD, Alexander JA, D’Aunno TA. Organizational correlates of access to primary care and mental health services in drug abuse treatment units. J Subst Abuse Treat. 1999;16:71–80. doi: 10.1016/S0740-5472(98)00018-X. [DOI] [PubMed] [Google Scholar]
  • 23.Grella CE, Etheridge RM, Joshi V, Anglin MD. Delivery of HIV risk-reduction services in drug treatment programs. J Subst Abuse Treat. 2000;19:229–237. doi: 10.1016/S0740-5472(00)00102-1. [DOI] [PubMed] [Google Scholar]
  • 24.Polinsky ML, Hser Y-I, Anglin MD, Maglione MA. Drug-user treatment programs in a large metropolitan area. Subst Use Misuse. 1998;33:1735–1761. doi: 10.3109/10826089809058953. [DOI] [PubMed] [Google Scholar]
  • 25.Astone J, Strauss SM, Vassilev ZP, Jarlais DC. Provision of hepatitis C education in a nationwide sample of drug treatment programs. J Drug Educ. 2003;33:107–117. doi: 10.2190/YEGL-GX4W-HGRA-EDC7. [DOI] [PubMed] [Google Scholar]
  • 26.Strauss SM, Astone J, Vassilev ZP, Jarlais DC, Hagan H. Gaps in the drug-free and methadone maintenance treatment program response to hepatitis C. J Subst Abuse Treat. 2003;24:291–297. doi: 10.1016/S0740-5472(03)00037-0. [DOI] [PubMed] [Google Scholar]
  • 27.Strauss SM, Falkin GP, Vassilev Z, Jarlais DC, Astone J. A nationwide survey of hepatitis C services provided by drug treatment programs. J Subst Abuse Treat. 2002;22:55–62. doi: 10.1016/S0740-5472(01)00213-6. [DOI] [PubMed] [Google Scholar]
  • 28.D’Aunno T, Vaughn TE, McElroy P. An institutional analysis of HIV prevention efforts by the nation’s outpatient drug abuse treatment units. J Health Soc Behav. 1999;40:175–192. doi: 10.2307/2676372. [DOI] [PubMed] [Google Scholar]
  • 29.D’Aunno TA, Vaughn TE. An organizational analysis of service patterns in outpatient drug abuse treatment units. J Subst Abuse. 1995;7:27–42. doi: 10.1016/0899-3289(95)90304-6. [DOI] [PubMed] [Google Scholar]
  • 30.Cronbach LJ. Coefficient α and the internal structure of tests. Psychometrika. 1951;16:297–334. doi: 10.1007/BF02310555. [DOI] [Google Scholar]
  • 31.Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med. 1998;338:286–290. doi: 10.1056/NEJM199801293380503. [DOI] [PubMed] [Google Scholar]
  • 32.Wong V, Wreghitt TG, Alexander GJM. A prospective study of hepatitis B vaccination in patients with chronic hepatitis C. Br Med J. 1996;312:1336–1337. doi: 10.1136/bmj.312.7042.1336. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Strauss SM, Astone J, Des Jarlais DC, Hagan H. The relationship between HIV testing and HCV antibody testing in methadone maintenance and drug-free treatment programs. Poster presented at: Sixty-fifth Annual Meeting of the College on Problems of Drug Dependence; June 16, 2003; Bal Harbour, FL.

Articles from Journal of Urban Health : Bulletin of the New York Academy of Medicine are provided here courtesy of New York Academy of Medicine

RESOURCES